Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies including Therapeutic Trials (ESCISIT)
Autore:
Swaak, AJG; van de Brink, H; Smeenk, RJT; Manger, K; Kalden, JR; Tosi, S; Marchesoni, A; Domljan, Z; Rozman, B; Logar, D; Pokorny, G; Kovacs, L; Kovacs, A; Vlachoyiannopoulos, PG; Moutsopoulos, HM; Chwalinska-Sadowska, H; Dratwianka, B; Kiss, E; Cikes, N; Anic, B; Schneider, M; Fischer, R; Bombardieri, S; Mosca, M; Graninger, W; Smolen, JS;
Indirizzi:
Zuiderziekenhuis, Dept Rheumatol, NL-3075 EA Rotterdam, Netherlands Zuiderziekenhuis Rotterdam Netherlands NL-3075 EA Rotterdam, Netherlands Netherlands Red Cross, Blood Transfus Serv, Cent Lab, Dept Autoimmune Dis,Amsterdam, Netherlands Netherlands Red Cross Amsterdam Netherlands Dis,Amsterdam, Netherlands Univ Erlangen Nurnberg, Dept Internal Med 3, Erlangen, Germany Univ Erlangen Nurnberg Erlangen Germany ternal Med 3, Erlangen, Germany Univ Erlangen Nurnberg, Inst Clin Immunol, Erlangen, Germany Univ ErlangenNurnberg Erlangen Germany Clin Immunol, Erlangen, Germany Ist Ortoped Gaetano Pini, Rheumatol Unit, Milan, Italy Ist Ortoped GaetanoPini Milan Italy Pini, Rheumatol Unit, Milan, Italy Univ Hosp Zagreb, Dept Rheumatol & Rehabil, Zagreb, Croatia Univ Hosp Zagreb Zagreb Croatia pt Rheumatol & Rehabil, Zagreb, Croatia Dr Peter Drzaj Hosp, Dept Rheumatol, Ljubljana, Slovenia Dr Peter Drzaj Hosp Ljubljana Slovenia t Rheumatol, Ljubljana, Slovenia Dr A Szent Gyorgyi Med Univ Ctr, Dept Internal Med 1, Szeged, Hungary Dr ASzent Gyorgyi Med Univ Ctr Szeged Hungary l Med 1, Szeged, Hungary Dr A Szent Gyorgyi Med Univ Ctr, Blood Transfus Inst, Szeged, Hungary Dr ASzent Gyorgyi Med Univ Ctr Szeged Hungary us Inst, Szeged, Hungary Natl Univ Athens, Sch Med, Dept Pathophysiol, Athens, Greece Natl Univ Athens Athens Greece h Med, Dept Pathophysiol, Athens, Greece Inst Rheumatol, Dept Connect Tissue Dis, Warsaw, Poland Inst Rheumatol Warsaw Poland l, Dept Connect Tissue Dis, Warsaw, Poland Debrecen Univ Med, Dept Internal Med, H-4012 Debrecen, Hungary Debrecen Univ Med Debrecen Hungary H-4012 Med, H-4012 Debrecen, Hungary Univ Hosp Ctr, Dept Med, Div Clin Immunol & Rheumatol, Zagreb, Croatia Univ Hosp Ctr Zagreb Croatia Clin Immunol & Rheumatol, Zagreb, Croatia Univ Dusseldorf, Dept Rheumatol, Med Clin, D-4000 Dusseldorf, Germany UnivDusseldorf Dusseldorf Germany D-4000 in, D-4000 Dusseldorf, Germany Univ Pisa, Dipartimento Med Interna, Pisa, Italy Univ Pisa Pisa ItalyUniv Pisa, Dipartimento Med Interna, Pisa, Italy Univ Vienna, Dept Rheumatol, Vienna, Austria Univ Vienna Vienna AustriaUniv Vienna, Dept Rheumatol, Vienna, Austria
Titolo Testata:
RHEUMATOLOGY
fascicolo: 1, volume: 40, anno: 2001,
pagine: 89 - 94
SICI:
1462-0324(200101)40:1<89:ILEROA>2.0.ZU;2-V
Fonte:
ISI
Lingua:
ENG
Soggetto:
CONNECTIVE-TISSUE DISEASES; ANTINUCLEAR ANTIBODIES; DERMATOMYOSITIS; IDENTIFICATION; CLASSIFICATION; POLYMYOSITIS; EVOLUTION; CRITERIA; COHORT;
Keywords:
SLE; incomplete; disease activity; prognosis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: Swaak, AJG Zuiderziekenhuis, Dept Rheumatol, Groeni Hilledijk 315, NL-3075EA Rotterdam, Netherlands Zuiderziekenhuis Groeni Hilledijk 315 RotterdamNetherlands NL-3075 EA
Citazione:
A.J.G. Swaak et al., "Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies including Therapeutic Trials (ESCISIT)", RHEUMATOLOG, 40(1), 2001, pp. 89-94

Abstract

Objective. Patients characterized with antinuclear antibodies (ANA) and disease symptoms related to one organ system can be described as having incomplete systemic lupus erythematosus (SLE). Thr aim of this multicentre studywas to describe the outcome of these so-called incomplete SLE patients. Two aspects of the outcome were studied: (i) the disease course, defined by the presence or absence of clinical symptoms: and (ii) the number of patients that eventually developed full SLE. Methods. Outcome parameters were the ACR criteria, the SLE: disease Activity Index (SLEDAI), the European Consensus Lupus Activity Measure (ECLAM) and the requirement for treatment. In 10 European rheumatology centres, patients who had been evaluated in the last 3 months of 1994 and had been diagnosed as having incomplete SLE on clinical grounds for at least yr were included in the study. All 122, patients who were included in the study were evaluated annually during 3 yr of follow-up. Results. Our results are confined to a patient cohort defined by disease duration of at least yr, being under clinical care at the different centres in Europe. These patients showed disease activity that was related mostly to symptoms of the skin and the musculoskeletal system, and leucocytopenia. During the follow-up, low doses of prednisolone were still being prescribedin 43%, of the patients. On recruitment to the study, 22 of the 112 incomplete SLE patients already fulfilled the ACR criteria for the diagnosis of SLE. Tn the 3 yr of follow-up only three patients developed SLE. Conclusions, A high proportion of patients in our cohort defined on clinical grounds as having incomplete SLE eventually showed disease activity defined by the SLEDAI as well as ECLAM. However, only three cases developed to SLE during the follow-up. This suggests that incomplete SLE forms a subgroup of SLE that has a good prognosis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 19:31:26